The effect of locally applied platelet-rich fibrin on donor sites and recipient sites after split-thickness skin transplantation

Submission date Recruitment status Prospectively registered 09/01/2006 No longer recruiting [] Protocol [] Statistical analysis plan Registration date Overall study status 17/02/2006 Completed [X] Results [] Individual participant data Last Edited Condition category Circulatory System 24/07/2014

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Ms Patricia Danielsen

Contact details

Bispebjerg Hospital Afdeling K Bispebjerg Bakke 23 2400 Kobenhavn NV Denmark 2400 +45 (0)3531 3463 patriciadanielsen@yahoo.dk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Study information

Scientific Title

Acronym

The Donor Study

Study objectives

Platelet-rich fibrin shortens wound healing time and improves aesthetic outcome

Ethics approval required

Old ethics approval format

Ethics approval(s)

Yes, 19/09/2005, ref: (KF)01286728

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Quality of life

Participant information sheet

Health condition(s) or problem(s) studied

Chronic leg ulcer

Interventions

Split-thickness skin transplantation

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Epithelialization on day five and nine post-operatively

Secondary outcome measures

- 1. Clinical appearance
- 2. Histological evaluation
- 3. Transepidermal Water Loss (TEWL)
- 4. Erythema
- 5. Microbiology
- 6. Incidence of infection
- 7. Unwanted side effects
- 8. Temperature difference between treated patients and control group patients

Overall study start date

01/01/2006

Completion date

01/04/2007

Eligibility

Key inclusion criteria

- 1. Patients undergoing surgery for chronic leg ulcer
- 2. Aged over 18 years
- 3. Written informed consent, the patient is expected to be able to complete the study
- 4. Donor site area from $2 \times (3 \text{ cm} \times 5 \text{ cm})$ to $2 \times (7.6 \text{ cm} \times 15 \text{ cm})$

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

20

Key exclusion criteria

- 1. Non-Danish speaking
- 2. Dementia
- 3. Pregnant or breastfeeding women
- 4. Patients treated with 10 mg of steroid or more daily
- 5. Patients that have received thrombocyte-inhibiting medicine less than four days before surgery
- 6. Patients not suited for general or spinal anaesthesia
- 7. Patients whose donor site has been used as a donor site before
- 8. Patients with skin diseases or pathological changes in the skin, including infection

Date of first enrolment 01/01/2006

Date of final enrolment 01/04/2007

Locations

Countries of recruitmentDenmark

Study participating centre Bispebjerg Hospital 2400 Kobenhavn NV Denmark 2400

Sponsor information

Organisation

Vivolution A/S (Denmark)

Sponsor details

Blokken 45 3460 Birkeroed Denmark 3460 +45 (0)4581 1962 info@vivolution.dk

Sponsor type

Industry

Website

http://www.vivolution.com

ROR

https://ror.org/010knjd35

Funder(s)

Funder type

Industry

Funder Name

Vivolution A/S (Denmark)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/11/2008		Yes	No
Results article	results	01/05/2013		Yes	No